Human ifn-alpha2 and pd-l1 overexpressing t cells for immune modulation of autoimmune and alloimmune disorders

Abstract

The present disclosure relates to cell therapy methods comprising administering a hematopoietic cell transplant comprising a population of genetically engineered T cells that overexpress PD-L1 and IFN-α2 (αρ-T cells) to a recipient subject in need thereof, wherein the recipient in need thereof is afflicted with an autoimmune or alloimmune disorder. The genetically engineered population of αρ-T cells is characterized by expansion in vitro, persistence in vivo, capacity to infiltrate target tissues; and sustained immune modulatory function. In one application, an administered allogeneic or autologous hematopoietic cell transplant suppresses graft versus host reactivity in a recipient subject with a hematologic cancer while preserving graft versus tumor immunity. In a second application, the administered hematopoietic cell transplant suppresses autoimmune disorders or disorders with an autoimmune component.

Dependencies are inferred from the claim text.